Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery

Alcon Research, Ltd0 个研究点目标入组 590 人开始时间: 2013年7月3日最近更新: 2015年8月4日

适应症

试验速览

暂无简介。

•- Planned cataract extraction by phacoemulsification with implantation of a posterior chamber intraocular lens;
•- History of Type 1 or 2 diabetes and non-proliferative diabetic retinopathy (NPDR) (mild, moderate, or severe) in the study eye;
•- Best-corrected visual acuity (BCVA) of 73 letters or worse in the study eye with expectation of improvement after surgery;
•- Understand and sign an informed consent document;
•- Other protocol-defined inclusion criteria may apply.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 177
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 413

•- Pre-existing macular edema in the study eye;
•- History in the study eye of retinal detachment, wet age-related macular degeneration, chronic or recurrent
•inflammatory eye disease, or prior procedures;
•- Planned cataract surgery in the fellow eye prior to the Day 90 postoperative study visit or through study exit;
•- Planned multiple procedures for the study eye during the cataract/intraocular lens;
•- Use of exclusionary medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids, as specified in protocol;
•- Participation in any other clinical study within 30 days of the screening visit;
•- Females of childbearing potential who are breast feeding, have a positive urine pregnancy test at screening, are not willing to undergo a urine pregnancy test upon entering or exiting the study, intend to become pregnant during the study, or do not agree to use adequate birth control methods for the duration of the study;
•- Other protocol-defined exclusion criteria may apply.

发起方

Alcon Research, Ltd